Increased Cell Proliferation as a Key Event in Chemical Carcinogenesis: Application in an Integrated Approach for the Testing and Assessment of Non-Genotoxic Carcinogenesis.
Christian StruppMarco CorvaroSamuel M CohenJ Christopher CortonKumiko OgawaLysiane RichertMiriam Naomi JacobsPublished in: International journal of molecular sciences (2023)
In contrast to genotoxic carcinogens, there are currently no internationally agreed upon regulatory tools for identifying non-genotoxic carcinogens of human relevance. The rodent cancer bioassay is only used in certain regulatory sectors and is criticized for its limited predictive power for human cancer risk. Cancer is due to genetic errors occurring in single cells. The risk of cancer is higher when there is an increase in the number of errors per replication (genotoxic agents) or in the number of replications (cell proliferation-inducing agents). The default regulatory approach for genotoxic agents whereby no threshold is set is reasonably conservative. However, non-genotoxic carcinogens cannot be regulated in the same way since increased cell proliferation has a clear threshold. An integrated approach for the testing and assessment (IATA) of non-genotoxic carcinogens is under development at the OECD, considering learnings from the regulatory assessment of data-rich substances such as agrochemicals. The aim is to achieve an endorsed IATA that predicts human cancer better than the rodent cancer bioassay, using methodologies that equally or better protect human health and are superior from the view of animal welfare/efficiency. This paper describes the technical opportunities available to assess cell proliferation as the central gateway of an IATA for non-genotoxic carcinogenicity.
Keyphrases
- cell proliferation
- papillary thyroid
- endothelial cells
- squamous cell
- transcription factor
- human health
- risk assessment
- lymph node metastasis
- squamous cell carcinoma
- magnetic resonance
- oxidative stress
- computed tomography
- pi k akt
- cell death
- machine learning
- dna methylation
- pluripotent stem cells
- young adults
- patient safety
- functional connectivity
- childhood cancer
- electronic health record
- signaling pathway
- genome wide
- adverse drug
- big data
- contrast enhanced
- data analysis